Analyzing Cost of Revenue: Pharming Group N.V. and Perrigo Company plc

Analyzing Cost of Revenue: Pharming Group N.V. vs. Perrigo Company plc

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. From 2014 to 2023, Perrigo Company plc consistently demonstrated a robust cost of revenue, averaging around $2.96 billion annually. This figure highlights Perrigo's significant market presence and operational scale. In contrast, Pharming Group N.V., a smaller player, averaged a cost of revenue of approximately $16.7 million, reflecting its niche market focus.

Key Insights

• Perrigo's Stability: Over the decade, Perrigo's cost of revenue fluctuated modestly, peaking in 2020 at $3.25 billion, a 24% increase from 2014.
• Pharming's Growth: Pharming showed remarkable growth, with its cost of revenue increasing by over 500% from 2014 to 2023, indicating strategic expansion.

This analysis underscores the contrasting scales and strategies of these two companies, offering valuable insights for investors and industry analysts.